- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 230
Douyu restarts $944m IPO plans
After temporarily halting the IPO in May due to US-China tensions, Douyu has relaunched its efforts with a target of $944m in proceeds and moved its proposed listing from NYSE to Nasdaq.
Jul 9, 2019PRG acquires Metalysis
Power Resources Group has bought University of Cambridge-founded metal power producer Metalysis, which had plunged into administration last month.
Jul 8, 2019IndiaMart takes stock of public market
IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.
Jul 8, 2019LiveRamp scores Data Plus Math acquisition
Comcast Ventures has exited television advertising analytics platform Data Plus Math in a reported $150m purchase by LiveRamp.
Jul 8, 2019Codiak revokes $86m IPO filing
Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.
Jul 5, 2019Red Dot marks acquisition spot
GMO and Telkom Indonesia-backed Red Dot Payments was valued at $65m in a deal in which Naspers subsidiary PayU bought a majority stake.
Jul 5, 2019Ucommune to move into IPO neighbourhood
The co-working space service is aiming to raise up to $200m in an initial public offering in the US next year, with multiple real estate developers in line for exits.
Jul 4, 2019Karuna caps off initial public offering
PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.
Jul 4, 2019Codiak revokes $86m IPO filing
Codiak Biosciences has withdrawn its proposed offering citing unfavourable market conditions, delaying an exit for investors including Alexandria Real Estate Equities.
Jul 4, 2019Morphic takes more money in $104m IPO
Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.
Jul 3, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


